JP2015524386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524386A5 JP2015524386A5 JP2015519211A JP2015519211A JP2015524386A5 JP 2015524386 A5 JP2015524386 A5 JP 2015524386A5 JP 2015519211 A JP2015519211 A JP 2015519211A JP 2015519211 A JP2015519211 A JP 2015519211A JP 2015524386 A5 JP2015524386 A5 JP 2015524386A5
- Authority
- JP
- Japan
- Prior art keywords
- bone
- subject
- sclerostin antibody
- sclerostin
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010065687 Bone loss Diseases 0.000 claims description 75
- 210000000988 bone and bone Anatomy 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 60
- 238000011282 treatment Methods 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 20
- 239000011707 mineral Substances 0.000 claims description 20
- 230000011164 ossification Effects 0.000 claims description 20
- 208000020084 Bone disease Diseases 0.000 claims description 19
- 208000001132 Osteoporosis Diseases 0.000 claims description 18
- 102000019307 Sclerostin Human genes 0.000 claims description 17
- 108050006698 Sclerostin Proteins 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 16
- 230000032683 aging Effects 0.000 claims description 14
- 230000037118 bone strength Effects 0.000 claims description 14
- 210000003625 skull Anatomy 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 claims description 8
- 102000058171 human SOST Human genes 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 206010058314 Dysplasia Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010031252 Osteomyelitis Diseases 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 210000003054 facial bone Anatomy 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 208000007056 sickle cell anemia Diseases 0.000 claims description 6
- 229940122361 Bisphosphonate Drugs 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010049088 Osteopenia Diseases 0.000 claims description 5
- 150000004663 bisphosphonates Chemical class 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 4
- 208000006386 Bone Resorption Diseases 0.000 claims description 4
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims description 4
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 claims description 4
- RCPOVANIIKXVTB-YPPRVYOWSA-N Galactosylhydroxylysine Chemical compound NCCCC[C@@H](C(O)=O)N(O)C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RCPOVANIIKXVTB-YPPRVYOWSA-N 0.000 claims description 4
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 4
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 claims description 4
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 claims description 4
- 102000004067 Osteocalcin Human genes 0.000 claims description 4
- 108090000573 Osteocalcin Proteins 0.000 claims description 4
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 claims description 4
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 claims description 4
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000033558 biomineral tissue development Effects 0.000 claims description 4
- 230000024279 bone resorption Effects 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000002591 computed tomography Methods 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 229960002591 hydroxyproline Drugs 0.000 claims description 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 238000002601 radiography Methods 0.000 claims description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 206010000599 Acromegaly Diseases 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 201000000736 Amenorrhea Diseases 0.000 claims description 3
- 206010001928 Amenorrhoea Diseases 0.000 claims description 3
- 206010006956 Calcium deficiency Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000024720 Fabry Disease Diseases 0.000 claims description 3
- 208000015872 Gaucher disease Diseases 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 208000017670 Juvenile Paget disease Diseases 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims description 3
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims description 3
- 208000012583 Menkes disease Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
- 206010031264 Osteonecrosis Diseases 0.000 claims description 3
- 208000013612 Parathyroid disease Diseases 0.000 claims description 3
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims description 3
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 3
- 102100038803 Somatotropin Human genes 0.000 claims description 3
- 208000002903 Thalassemia Diseases 0.000 claims description 3
- 208000024799 Thyroid disease Diseases 0.000 claims description 3
- 208000026928 Turner syndrome Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010047623 Vitamin C deficiency Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 208000008321 Winchester syndrome Diseases 0.000 claims description 3
- 208000022567 adolescent idiopathic scoliosis Diseases 0.000 claims description 3
- 201000007930 alcohol dependence Diseases 0.000 claims description 3
- 231100000540 amenorrhea Toxicity 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 208000015322 bone marrow disease Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 239000000122 growth hormone Substances 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000024884 ischemic bone disease Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- 208000008585 mastocytosis Diseases 0.000 claims description 3
- 230000005906 menstruation Effects 0.000 claims description 3
- 230000001617 migratory effect Effects 0.000 claims description 3
- 201000004931 neurofibromatosis Diseases 0.000 claims description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000005368 osteomalacia Diseases 0.000 claims description 3
- 208000029985 osteonecrosis of the jaw Diseases 0.000 claims description 3
- 208000022560 parathyroid gland disease Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000002784 sclerotic effect Effects 0.000 claims description 3
- 208000010233 scurvy Diseases 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 claims description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 2
- 206010058359 Hypogonadism Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000001826 Marfan syndrome Diseases 0.000 claims description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 2
- 102000013814 Wnt Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 230000018678 bone mineralization Effects 0.000 claims description 2
- 230000002308 calcification Effects 0.000 claims description 2
- 230000022159 cartilage development Effects 0.000 claims description 2
- 238000000423 cell based assay Methods 0.000 claims description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 2
- 208000002865 osteopetrosis Diseases 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 229960001251 denosumab Drugs 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000000123 anti-resoprtive effect Effects 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 2
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 2
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668210P | 2012-07-05 | 2012-07-05 | |
| US61/668,210 | 2012-07-05 | ||
| US201361782072P | 2013-03-14 | 2013-03-14 | |
| US61/782,072 | 2013-03-14 | ||
| PCT/EP2013/064052 WO2014006100A1 (en) | 2012-07-05 | 2013-07-03 | Treatment for bone diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019075787A Division JP6878492B2 (ja) | 2012-07-05 | 2019-04-11 | 骨疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524386A JP2015524386A (ja) | 2015-08-24 |
| JP2015524386A5 true JP2015524386A5 (enExample) | 2016-09-08 |
| JP6770312B2 JP6770312B2 (ja) | 2020-10-14 |
Family
ID=48745968
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519211A Active JP6770312B2 (ja) | 2012-07-05 | 2013-07-03 | 骨疾患の治療 |
| JP2019075787A Active JP6878492B2 (ja) | 2012-07-05 | 2019-04-11 | 骨疾患の治療 |
| JP2021075463A Active JP7350028B2 (ja) | 2012-07-05 | 2021-04-28 | 骨疾患の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019075787A Active JP6878492B2 (ja) | 2012-07-05 | 2019-04-11 | 骨疾患の治療 |
| JP2021075463A Active JP7350028B2 (ja) | 2012-07-05 | 2021-04-28 | 骨疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9925260B2 (enExample) |
| EP (2) | EP2869844B2 (enExample) |
| JP (3) | JP6770312B2 (enExample) |
| CN (1) | CN104619342A (enExample) |
| AU (1) | AU2013285488B2 (enExample) |
| WO (1) | WO2014006100A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| KR102584953B1 (ko) | 2015-03-13 | 2023-10-04 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항 스클레로스틴 항체, 이의 항원 결합 단편 및 의학적 용도 |
| CN110214021A (zh) * | 2016-08-08 | 2019-09-06 | 安进公司 | 使用抗硬化蛋白抗体改善结缔组织附着的方法 |
| KR102550414B1 (ko) * | 2016-11-03 | 2023-07-04 | 삼성전자주식회사 | 반도체 소자의 제조 방법 |
| JP2020502218A (ja) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ ３ リミテッド | 骨形成不全症の処置における抗スクレロスチン抗体の使用 |
| WO2020014330A1 (en) * | 2018-07-10 | 2020-01-16 | Academia Sinica | A biomarker and target for diagnosis, prognosis and treatment of ankylosing spondylitis |
| RU2720827C1 (ru) * | 2019-09-27 | 2020-05-13 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр гематологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ гематологии" Минздрава России) | Способ определения степени выраженности патологической инфильтрации костного мозга при болезни Гоше |
| CN111632147A (zh) * | 2020-06-07 | 2020-09-08 | 重庆医科大学 | 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用 |
| WO2024102685A2 (en) * | 2022-11-07 | 2024-05-16 | Memorial Sloan-Kettering Cancer Center | Antigen-recognizing receptors targeting b7-h3 and uses thereof |
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US330330A (en) * | 1885-11-10 | Geoegb hutchins howe | ||
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| JPH06502311A (ja) | 1990-10-22 | 1994-03-17 | フォックス・チェイス・キャンサー・センター | Ｒｎａ療法を提供するためのｄｎａ構造 |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| NZ267838A (en) | 1993-06-07 | 1997-12-19 | Genentech Inc | Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| ATE378407T1 (de) | 1994-04-29 | 2007-11-15 | Curis Inc | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
| DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| DE69738868D1 (de) | 1996-05-22 | 2008-09-11 | Viventia Biotech Inc | Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
| AU8555798A (en) | 1997-08-01 | 1999-02-22 | Genset | 5' ests for secreted proteins expressed in muscle and other mesodermal tissues |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6395511B1 (en) | 1998-11-27 | 2002-05-28 | Darwin Discovery, Ltd. | Nucleic acids encoding a novel family of TGF-β binding proteins from humans |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| CA2361553A1 (en) | 1999-01-29 | 2000-08-03 | Zhenping Zhu | Antibodies specific to kdr and uses thereof |
| DE60042799D1 (de) | 1999-06-09 | 2009-10-01 | Genentech Inc | Methoden zur Diagnose von Tumoren |
| JP2003525611A (ja) | 2000-03-02 | 2003-09-02 | アムジェン インコーポレーテッド | コルディン様−２分子およびその使用 |
| MXPA02011808A (es) | 2000-06-01 | 2003-04-10 | Amgen Inc | Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos. |
| WO2001098491A2 (en) | 2000-06-19 | 2001-12-27 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| CA2421056A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | A polypeptide for use as a diagnostic marker for the presence of colon tumours |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
| CA2469025A1 (en) | 2001-12-06 | 2003-06-19 | Biocontrol Systems, Inc. | Sample collection and testing system |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| AU2003223214B2 (en) | 2002-03-01 | 2008-09-18 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| ES2379689T3 (es) | 2003-03-14 | 2012-04-30 | Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware | Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| NZ544618A (en) | 2003-06-16 | 2009-02-28 | Celltech R & D Inc | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
| ES2414460T3 (es) | 2004-08-04 | 2013-07-19 | Amgen Inc. | Anticuerpos para Dkk-1 |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| EP1981910B1 (en) | 2006-01-13 | 2013-06-26 | A Chan Holding B.V. | Method for identifying inhibitor of the glypican-sclerostin interaction |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| FI3345607T3 (fi) | 2006-12-29 | 2022-11-30 | Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia | |
| MX2009008096A (es) | 2007-02-02 | 2009-08-07 | Novartis Ag | Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos. |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| ES2560532T3 (es) | 2007-11-02 | 2016-02-19 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6) |
| BRPI0819688A2 (pt) | 2007-12-14 | 2015-06-16 | Amgen Inc | Processo para tratamento de fratura óssea com anticorpos anti-esclerostina. |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| WO2010100200A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
| WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| TWI636993B (zh) | 2010-10-27 | 2018-10-01 | 安美基公司 | Ｄｋｋ１抗體及使用方法 |
-
2013
- 2013-07-03 WO PCT/EP2013/064052 patent/WO2014006100A1/en not_active Ceased
- 2013-07-03 AU AU2013285488A patent/AU2013285488B2/en active Active
- 2013-07-03 EP EP13733322.5A patent/EP2869844B2/en active Active
- 2013-07-03 US US13/934,433 patent/US9925260B2/en active Active
- 2013-07-03 JP JP2015519211A patent/JP6770312B2/ja active Active
- 2013-07-03 EP EP19205429.4A patent/EP3626267A1/en active Pending
- 2013-07-03 CN CN201380046487.0A patent/CN104619342A/zh active Pending
-
2018
- 2018-02-02 US US15/887,299 patent/US10799583B2/en active Active
-
2019
- 2019-04-11 JP JP2019075787A patent/JP6878492B2/ja active Active
-
2020
- 2020-09-14 US US17/020,108 patent/US11896667B2/en active Active
-
2021
- 2021-04-28 JP JP2021075463A patent/JP7350028B2/ja active Active
-
2024
- 2024-01-08 US US18/406,593 patent/US20240269274A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524386A5 (enExample) | ||
| JP2010539190A5 (enExample) | ||
| HRP20201438T1 (hr) | Metoda inhibiranja resorpcije kosti | |
| US20240269274A1 (en) | Treatment for bone diseases | |
| HRP20130803T1 (hr) | Sredstva za vezanje sklerostina | |
| JP2008539726A5 (enExample) | ||
| US20240400664A1 (en) | Anti-Sclerostin Antibodies and Their Use to Treat Bone Disorders as Part of a Regimen | |
| US9913900B2 (en) | Method of treating alvelor bone loss through the use of anti-sclerostin antibodies | |
| HRP20170679T1 (hr) | Epitopi sklerostina | |
| HRP20201366T1 (hr) | Metoda liječenja osteoporoze | |
| EP2739311B9 (en) | Method for treating bone gap defects | |
| HK40014911A (en) | Treatment for bone diseases | |
| HK1196251A (en) | Method for treating bone gap defects | |
| RU2019129618A (ru) | Анти-il31 антитела для применения в ветеринарии |